{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:26:43Z","timestamp":1792758403409,"version":"4.5.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["HHSD2002013M53964B"],"award-info":[{"award-number":["HHSD2002013M53964B"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Public Health Rep"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Opioid use disorder (OUD) affects approximately 5.6 million people in the United States annually, yet rates of the use of effective medication for OUD (MOUD) treatment are low. We conducted an observational cohort study from August 2017 through May 2021, the MOUD Study, to better understand treatment engagement and factors that may influence treatment experiences and outcomes. In this article, we describe the study design, data collected, and treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We recruited adult patients receiving OUD treatment at US outpatient facilities for the MOUD Study. We collected patient-level data at 5 time points (baseline to 18 months) via self-administered questionnaires and health record data. We collected facility-level data via questionnaires administered to facility directors at 2 time points. Across 16 states, 62 OUD treatment facilities participated, and 1974 patients enrolled in the study. We summarized descriptive data on the characteristics of patients and OUD treatment facilities and selected treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Approximately half of the 62 facilities were private, nonprofit organizations; 62% focused primarily on substance use treatment; and 20% also offered mental health services. Most participants were receiving methadone (61%) or buprenorphine (32%) and were predominately non-Hispanic White (68%), aged 25-44 years (62%), and female (54%). Compared with patient-reported estimates at baseline, 18-month estimates suggested that rates of abstinence increased (55% to 77%), and rates of opioid-related overdoses (7% to 2%), emergency department visits (9% to 4%), and arrests (15% to 7%) decreased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our results demonstrated the benefits of treatment retention not only on abstinence from opioid use but also on other quality-of-life metrics, with data collected during an extended period. The MOUD Study produced rich, multilevel data that can lay the foundation for an evidence base to inform OUD treatment and support improvement of care and patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00333549231222479","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:31:26Z","timestamp":1706153486000},"page":"484-493","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder"],"prefix":"10.1177","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-9605","authenticated-orcid":false,"given":"Jill A.","family":"Dever","sequence":"first","affiliation":[{"name":"RTI International, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marci F.","family":"Hertz","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Dunlap","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Richardson","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park, NC, USA"},{"name":"Current affiliation: Stop Soldier Suicide, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Beth","family":"Wolicki","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley B.","family":"Biggers","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Edlund","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele K.","family":"Bohm","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Turcios","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Evans","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Gery P.","family":"Guy","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"bibr1-00333549231222479","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2021 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2022. Accessed July 8, 2023. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report"},{"key":"bibr2-00333549231222479","unstructured":"US Food and Drug Administration. Information about medication-assisted treatment (MAT). 2019. Accessed May 31, 2022. https:\/\/www.fda.gov\/drugs\/information-drug-class\/information-about-medication-assisted-treatment-mat"},{"key":"bibr3-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001394"},{"key":"bibr4-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"bibr5-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13113"},{"key":"bibr6-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06257-4"},{"key":"bibr7-00333549231222479","doi-asserted-by":"publisher","DOI":"10.31478\/202004b."},{"key":"bibr8-00333549231222479","first-page":"109","volume-title":"Medications for Opioid Use Disorder Save Lives","volume":"2019","author":"National Academies\u2019 Committee on Medication-Assisted Treatment for Opioid Use Disorder"},{"key":"bibr9-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06255-6"},{"key":"bibr10-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.07.005"},{"key":"bibr11-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108329"},{"key":"bibr12-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108710"},{"key":"bibr13-00333549231222479","unstructured":"Centers for Disease Control and Prevention. Medications for Opioid Use Disorder Study (MOUD Study). 2018. Page last reviewed January 24, 2022. Accessed July 8, 2023. https:\/\/www.cdc.gov\/opioids\/framework\/surveillance-research\/moud-study.html"},{"key":"bibr14-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1080208"},{"key":"bibr15-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0338"},{"key":"bibr16-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108008"},{"key":"bibr17-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1007\/s11414-018-9629-4"},{"key":"bibr18-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107654"},{"key":"bibr19-00333549231222479","first-page":"25","volume-title":"The Opioid Epidemic and Infectious Diseases","volume":"2021","author":"Akhtar WZ"},{"key":"bibr20-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1891492"},{"key":"bibr21-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0402-3"},{"key":"bibr22-00333549231222479","unstructured":"Pew Charitable Trusts. Opioid use disorder: challenges and opportunities in rural communities. 2019. Accessed July 8, 2023. https:\/\/www.pewtrusts.org\/-\/media\/assets\/2019\/02\/opioiduseruralcommunities_final.pdf"},{"key":"bibr23-00333549231222479","unstructured":"Substance Abuse and Mental Health Services Administration. 2016 National directory of drug and alcohol abuse treatment facilities. June 30, 2016. Accessed January 11, 2018. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/directory_2016.pdf"},{"key":"bibr24-00333549231222479","unstructured":"US Census Bureau. Geographic levels. October 8, 2021. Accessed September 29, 2023. https:\/\/www.census.gov\/programs-surveys\/economic-census\/guidance-geographies\/levels.html"},{"key":"bibr25-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1595\/003214075X1912929"},{"key":"bibr26-00333549231222479","unstructured":"National Center for Health Statistics. NCHS urban\u2013rural classification scheme for counties. June 1, 2017. Accessed February 10, 2020. https:\/\/www.cdc.gov\/nchs\/data_access\/urban_rural.htm"},{"key":"bibr27-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/s0740-5472(02)00241-6"},{"key":"bibr28-00333549231222479","unstructured":"Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health (NSDUH): CAI Specifications for Programming (English Version). Substance Abuse and Mental Health Services Administration; 2015. Accessed January 8, 2018. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUHmrbCAIquex2016v2.pdf"},{"key":"bibr29-00333549231222479","unstructured":"Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance Survey questionnaire. 2015. Accessed January 8, 2018. https:\/\/www.cdc.gov\/brfss\/questionnaires\/index.htm"},{"key":"bibr30-00333549231222479","unstructured":"EuroQol Research Foundation. EQ-5D-3L user guide. 2018. Accessed October 3, 2023. https:\/\/euroqol.org\/eq-5d-instruments"},{"key":"bibr31-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1207\/s15327752jpa5201_2"},{"key":"bibr32-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1007\/s10862-012-9323-4"},{"key":"bibr33-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1111\/add.13238"},{"key":"bibr34-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1604339"},{"key":"bibr35-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.02.030"},{"key":"bibr36-00333549231222479","unstructured":"ASAM. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. American Society of Addiction Medicine; 2020. Accessed April 4, 2022. https:\/\/www.asam.org\/Quality-Science\/quality\/2020-national-practice-guideline"},{"key":"bibr37-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32812-X"},{"key":"bibr38-00333549231222479","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0227"},{"key":"bibr39-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1177\/2150132720931720"},{"key":"bibr40-00333549231222479","doi-asserted-by":"publisher","DOI":"10.1093\/jssam\/smx019"},{"key":"bibr41-00333549231222479","first-page":"368","volume-title":"Hard-to-Survey Populations","volume":"2014","author":"Berry SH"}],"container-title":["Public Health Reports\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00333549231222479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00333549231222479","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00333549231222479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:39:27Z","timestamp":1777628367000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00333549231222479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/00333549231222479"],"URL":"https:\/\/doi.org\/10.1177\/00333549231222479","relation":{},"ISSN":["0033-3549","1468-2877"],"issn-type":[{"value":"0033-3549","type":"print"},{"value":"1468-2877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}